



**Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research**

MEMORANDUM

From: Shaokui Wei, MD, MPH
Epidemiologist, Pharmacovigilance Branch 3 (PB3)
Division of Pharmacovigilance (DPV)
Office of Biostatistics and Pharmacovigilance (OBPV)
Center for Biologics Evaluation and Research (CBER)

To: Brendan Day, MD, MPH
Acting Director, DPV, OBPV, CBER

Subject: Safety and Utilization Review for the Pediatric Advisory Committee (PAC)

Applicant: SeaStar Medical, Inc.

Product: QUELIMMUNE [Selective Cytopheretic Device for Pediatrics (SCD-PED)]

STN: HDE# BH 220740.18

Indication: Intended to treat pediatric patients (weight ≥ 10 kg and age ≤ 22 years) with acute kidney injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring renal replacement therapy (RRT)

Meeting Date: Pediatric Advisory Committee Meeting, September 16, 2026

Table of Contents

I. INTRODUCTION	3
II. BACKGROUND	3
III. DEVICE DESCRIPTION	3
IV. INDICATIONS FOR USE	5
V. REGULATORY HISTORY	5
VI. ANNUAL DISTRIBUTION NUMBER/ANNUAL SALES NUMBERS	6
VII. LABEL CHANGES IN REVIEW PERIOD	7
VIII. MEDICAL DEVICE REPORTS (MDRs)	7
IX. ANNUAL REPORT REVIEW	8
X. POST-APPROVAL STUDY (PAS) REPORT REVIEW	8
XI. POSTMARKET LITERATURE REVIEW	9
XII. SUMMARY	9

I. INTRODUCTION

In accordance with the Pediatric Medical Device Safety and Improvement Act, this review provides a safety update for the Pediatric Advisory Committee (PAC), based on the postmarket experience with the use of a humanitarian use device, Selective Cytopheretic Device for Pediatrics (SCD-PED), manufactured by SeaStar Medical with the trade name, QUELIMMUNE. This review provides updated postmarket safety data, so the Committee can advise the Food and Drug Administration (FDA) on potential safety concerns associated with the use of this device in children. This memorandum documents FDA's complete evaluation, including review of postmarket medical device reporting (MDR) of adverse events, annual reports from the manufacturer, post-approval study report, and the peer-reviewed literature associated with the device.

II. BACKGROUND

Acute Kidney Injury (AKI) may become a critical and life-threatening condition that profoundly affects pediatric patients, particularly those in the pediatric intensive care unit (PICU) requiring Continuous Kidney Replacement Therapy (CKRT) and those with concomitant sepsis or a septic condition. The confluence of sepsis and AKI in children presents a particularly challenging clinical scenario, marked by a heightened risk of poor outcomes, including increased mortality rates.

Patients with AKI experience a systemic inflammatory response with activated circulating leukocytes playing a central role in this process. The response includes increased production of cytokines, activation of polymorphonuclear leukocytes (PMNs), and increased expression of leukocyte adhesion molecules, which further contributes to AKI and other organ dysfunction.


Pediatric sepsis associated with AKI is characterized by a dysregulated immune response, systemic inflammation, and endothelial dysfunction, all of which contribute to the historically poor outcomes observed in this population.

III. DEVICE DESCRIPTION

The SCD-PED is comprised of tubing, connectors, and a synthetic hollow-fiber membrane cartridge. The SCD-PED is connected in-line to an existing, commercially available CKRT circuit device as outlined in Figure 1 below. After the CKRT hemofilter, blood is diverted to the extra capillary space (ECS) of the SCD. Blood circulates through this space and then returns to the patient via the venous return line of the CKRT circuit. Of note, the blood flow path in the SCD-PED is non-sterile. A therapeutic post-cartridge

ionized calcium level (of < 0.40 mmol/L for $> 90\%$ of treatment time) is achieved with Regional Citrate Anticoagulation (RCA) for the entire CKRT and SCD blood circuits.

Figure 1: Schematic of the CKRT circuit and SCD-PED



The diagram illustrates the technical configuration and flow pathways used in advanced renal replacement therapy, specifically showing how the SCD-PED system integrates with standard CKRT equipment to provide enhanced treatment capabilities for patients requiring intensive kidney support. The CKRT circuit displayed has the following components: a line representing the pathway for blood flow from the patient to the hemofilter followed by a line for the venous return for blood flow back to the patient in standard CKRT equipment; for SCD therapy, there is a line for blood flow from the patient to the SCD cartridge, a specialized component for enhanced detoxification therapy, and the venous return line from the SCD cartridge back to the patient; and multiple interconnected lines and connections that facilitate the flow of blood and dialysate through the treatment system.

The SCD-PED cartridge incorporates a synthetic hollow fiber membrane which can bind activated leukocytes to its extracapillary surface.

Patients with AKI can experience cytokine storm and hyperinflammation from activated neutrophils that can release cytokines and other pro-inflammatory mediators, which may worsen clinical outcomes. The fiber membrane lining the walls of the cartridge, together with the low ionized calcium level is intended to promote binding of activated neutrophils and monocytes to the fibers, resulting in overall decrease in inflammatory mediators.

IV. INDICATIONS FOR USE

The SCD-PED is intended to treat pediatric patients (weight $\geq 10\text{kg}$ and age ≤ 22 years) with acute kidney injury (AKI) due to sepsis or a septic condition on antibiotic therapy and requiring renal replacement therapy (RRT).

V. REGULATORY HISTORY

The pediatric clinical study SCD-PED-01 to support this Humanitarian Device Exemption (HDE) was approved to proceed under investigational device exemption (IDE # G150179) on September 15, 2015, by the Center for Devices and Radiological Health (CDRH)¹. CDRH had original jurisdiction over the HDE, and the study was conducted in accordance with 21 CFR Parts 50, 56, and 812.

The IDE was subsequently transferred to Center for Biologics Evaluation and Research (CBER) in October 2021, based on determination that the device output includes more than minimally manipulated biologic products (leukocytes).

The SCD-PED was approved in the US on February 21, 2024. The initial approval letter (BH220740/0) included the following conditions of approval (CoA):

“A Humanitarian Device Exemption (HDE) Surveillance Registry: The surveillance registry will be carried out to collect safety data on clinical use of SCD-PED under the HDE. The study outcomes include new (secondary) blood stream infections (BSIs) within 28 days from the time of SCD-PED initiation or through hospital discharge, whichever is sooner. All patients initiated on SCD-PED therapy under the HDE-approved indication will be enrolled into the surveillance registry. A closely matched comparator cohort will be identified from the Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK) registry. A minimum of 300 patients will be enrolled in the registry within two years from the HDE approval. All patients will be followed for 90 days following treatment.

The study milestones are as follows:

- Final Study Protocol: February 20, 2024 (submitted)
- From the date of study protocol approval, you must meet the following timelines for
 - First subject enrolled within 6 months: August 20, 2024
 - 20% of subjects enrolled within 12 months: February 20, 2025
 - 50% of subjects enrolled within 18 months: August 20, 2025
 - 100% of subjects enrolled within 24 months: February 20, 2026

¹ This started as a pilot study and then changed to pivotal study for HDE after HUD was granted in June 2020.

- Study Completion date: May 30, 2026
- Final Study Report: August 31, 2026”

The updated PAS protocol: SCD-PED-HDE-1, Version 1.4, submitted under HDE BH220740.13, was approved on November 26, 2025. In the updated PAS protocol, the sample size was revised from 300 patients to 50 patients. (see details in Section X. Post-Approval Study Report).

Based on correspondence dated July 19, 2026, the sponsor is preparing a final study report for the FDA, to be submitted in August 2026. There are 65 patients enrolled to date. The sponsor recognizes the value of collecting additional real-world clinical data, and remains committed to generating meaningful evidence for patients, physicians, and the FDA; therefore, the sponsor will continue to facilitate enrollment where feasible, understanding that certain hospitals may not have the resources to support research.

VI. ANNUAL DISTRIBUTION NUMBER/ANNUAL SALES NUMBERS

Section 520(m)(6)(A)(ii) of the FD&C allows HDEs indicated for pediatric use to be sold for profit as long as the number of devices distributed in any calendar year does not exceed the annual distribution number (ADN).

The currently approved ADN for SCD-PED is (b) (4) SCD-PED sets. The ADN was calculated as $\frac{(b) (4)}{(4)} \text{ SCD-PED sets} \times 8,000 \text{ individuals} = (b) (4) \text{ SCD-PED sets}$; where the 7 SCD-PED sets is derived from (b) (4) of therapy where the cartridge and tubing set are replaced every 24 hours (the duration of use for the SCD-PED device ranged from 1-7 days and the SCD-PED Cartridge and SCD blood tubing set are to be replaced every 24 hours of use throughout the duration of therapy); 8000 individuals represent the target population per the HDE definition at the time the labeling was approved (February 2024).

The number of SCD-PED sets distributed has not exceeded the ADN. The number of SCD-PED sets distributed during:

- Calendar year 2025: (b) (4) sets
- Calendar year 2026: Not yet available, however, from January 1, 2026, through June 30, 2026, SeaStar distributed (b) (4) sets

Note: These estimates were provided by the manufacturer for FDA review. Distribution data is protected as confidential commercial information and may require redaction from this review.

During the PAC review period, July 1, 2025, to June 30, 2026, (b) (4) pediatric patients were treated with SCD-PED.

VII. LABEL CHANGES IN REVIEW PERIOD

There were no safety related label changes during the PAC review period (July 1, 2025, to June 30, 2026).

VIII. MEDICAL DEVICE REPORTS (MDRs)

A. Strengths and Limitations of MDR Data

The FDA receives MDRs of suspected device-associated deaths, serious injuries, and malfunctions from mandatory reporters (manufacturers, importers, and device user facilities) and voluntary reporters such as health care professionals, patients, and consumers. The FDA uses MDRs to monitor device performance, detect potential device-related safety issues, and contribute to benefit-risk assessments of these products.

MDR reports can be used to:

- Establish a qualitative snapshot of adverse events for a device or device type
- Detect actual or potential device problems including:
 - rare or unexpected adverse events;
 - adverse events that occur during long-term use;
 - adverse events associated with vulnerable populations;
 - off-label use; and use error.

Although MDRs are a valuable source of information, this Medical Device Reporting is a passive surveillance system and has limitations, including the submission of incomplete, inaccurate, untimely, unverified and/or additionally biased data. In addition, the incidence of an event cannot be determined from MDRs alone due to under-reporting of events and lack of information about frequency of device use.

Limitations of MDRs include:

- MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time, or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices.
- Confirming whether a device actually caused an event can be difficult based solely on information provided in MDRs. Establishing a cause-and-effect relationship is especially difficult if circumstances surrounding the event have not been verified or if the device in question has not been directly evaluated.
- MDR data is subjected to reporting bias due to reporting practices, increased media attention, and/or other agency regulatory actions.
- MDR data does not represent all known safety information for a reported

medical device and should be interpreted in the context of other available information when making device-related or treatment decisions.

B. MDRs Associated with SCD-PED

The MDR database was searched on July 2, 2026, to identify postmarket adverse event reports associated with the use of SCD-PED submitted to FDA during the PAC review period, July 1, 2025, to June 30, 2026. There were no MDRs identified in FDA Manufacturer and User Facility Device Experience (MAUDE) database.

IX. ANNUAL REPORT REVIEW


The sponsor's second annual report was received on February 21, 2026, which covered the 1-year reporting period following the last annual report (received February 21, 2025).

The annual report states that there have been zero device-related events reported among treated patients (see details in Section X. Post-Approval Study Report).

X. POST-APPROVAL STUDY (PAS) REPORT REVIEW

SeaStar Medical is conducting a PAS per the requirements set forth on February 21, 2024, HDE Approval Order for HDE Surveillance Registry (see Section V Regulatory History). This study is an observational registry of patients who are treated with QUELIMMUNE as part of routine clinical care for their condition. The updated PAS protocol: SCD-PED-HDE-1, Version 1.4, submitted under HDE BH220740.13, was approved on November 26, 2025. In the updated PAS protocol, the sample size was revised from 300 patients to 50 patients. This determination was based on several factors: the device's low utilization in clinical settings, especially in pediatric patients; the low number of exposed patients; and the fact that all patients are receiving antibiotics.

The most recent PAS progress report, the PAS top-line study report submitted under HDE BH220740.17, was received on June 1, 2026. The report summarized post-approval surveillance data from 50 patients enrolled in the registry through Day 28 following treatment with QUELIMMUNE. (b) (4)



(b) (4)



XI. POSTMARKET LITERATURE REVIEW

A PubMed literature search conducted on July 8, 2026, using the search term "QUELIMMUNE" OR "Selective Cytopheretic Device for Pediatrics" for articles published between July 1, 2025, and June 30, 2026, retrieved 7 articles. Titles and abstracts were reviewed for relevance to safety information specifically for SCD-PED, and one article was identified (listed below). No new safety concern was identified.

Article	Author's conclusions
Goldstein SL, Krallman KA, Harris M, et al. Early post-approval experience of the selective cytopheretic device surveillance registry for pediatric AKI requiring kidney replacement therapy. <i>Pediatr Nephrol.</i> 2026 Jul;41(7):2205-2212.	This initial real-world experience of SCD-PED therapy in pediatric AKI with sepsis in patients requiring CKRT suggests no device-related infections and similar improved clinical outcomes consistent with the previous trial SCD-PED experience in this critically ill population.

XII. SUMMARY

FDA did not identify new safety signals during this comprehensive postmarketing safety review that included review of the manufacturer's annual report, the PAS report, and the literature published during the PAC review period. There were no MDRs received by FDA during this review period. The HDE for this device remains appropriate for the pediatric populations for which it was granted. FDA will continue routine monitoring of the safety and distribution data for this device.